Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Testa

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Diabetes|September 8, 2016
Activation of the Pro-Oxidant PKCβII-p66Shc Signaling Pathway Contributes to Pericyte Dysfunction in Skeletal Muscles of Patients With Diabetes With Critical Limb IschemiaRosa Vono, Claudia Fuoco, Stefano Testa, et al.
Immunity|November 22, 2025
IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapyHua Jiang, Sam Limsuwannarot, Kayla R Kulhanek, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032Stefano Testa, Jonathon E Himes, Ajay Subramanian, et al.
Cancer Discovery|March 5, 2026
Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 resultsJie Deng, Aastha Pal, Stefano Testa, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Diabetes|September 8, 2016
Activation of the Pro-Oxidant PKCβII-p66Shc Signaling Pathway Contributes to Pericyte Dysfunction in Skeletal Muscles of Patients With Diabetes With Critical Limb IschemiaRosa Vono, Claudia Fuoco, Stefano Testa, et al.
Immunity|November 22, 2025
IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapyHua Jiang, Sam Limsuwannarot, Kayla R Kulhanek, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032Stefano Testa, Jonathon E Himes, Ajay Subramanian, et al.
Cancer Discovery|March 5, 2026
Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 resultsJie Deng, Aastha Pal, Stefano Testa, et al.
Pageof 5